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Malignant hictiocytosis (MH) and true 
histiocytic lymphoma (THL) are hematopoie- 
tic malignancies of the mononuclear phago- 
cytic system distinguished from each other 
by clinical presentation and presumed cell 
of origin. THL present as a localized mass 
derived from the fixed tissue histiocyte 
which mayor may not disseminate. MH orig- 
inates from the circulating monocyte or tis- 
sue macrophage and is characterized by a 
syndrome of systemic symptoms, pancy- 
topenia, adenopathy, hepatosplenomegaly, 
and wasting. The distinction between MH 
and THL is at times arbitrary and overlap ex- 
ists between these syndromes. The clinico- 
pathologic studies that defined these enti- 
ties were performed prior to the 
development of immunophenotyping and 
other molecular techniques currently used 
to ensure proper classification of he- 
matopoietic malignancies. Nine patients 
from the University of Minnesota originally 
diagnosed with MH were retrospectively an- 
alyzed using a panel of antibodies reactive 
against T cell, B cell, and myelomonocytic 
antigens. Only one patient was reclassified 
as a possible histiocytic malignancy after re- 
evaluation. Similar immunophenotyping 
studies have also shown cases previously di- 
agnosed as MH or THL express lymphoid 
antigens, and would now be classified as 
Ki-I positive anaplastic large cell lymphoma 
(ALCL) or some other hematopoietic neo- 
plasm. These results indicate true histiocytic 
neoplasms are extremely rare, and previous 
concepts concerning clinical presentation 
and therapeutic outcome of the entities are 
inaccurate. In this paper we summarize the 
results of multiple retrospective analyses of 
cases previously diagnosed as MH or THL, 
including our experience at University of 
Minnesota, to illustrate the overall rarity of 
these entities. The current literature on ma- 
lignant histiocytic disorders is reviewed, and 
the clinical presentation of patients deter- 
mined to have histiocytic malignancies using 
contemporary analytical techniques i s  
discussed. Q 1995 ~ i ~ e y - ~ i s s ,  Inc. 
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INTRODUCTION 
Tumors of presumed histiocytic origin are a controver- 
sial subset of hematopoietic malignancies including true 
histiocytic lymphoma (THL) and malignant histiocytosis 
(MH). THL is defined as a focal proliferation of malig- 
nant histiocytes which may or may not disseminate. MH 
is characterized a syndrome of fever, wasting, pancy- 
topenia, hepatosplenomegaly , adenopathy , and a sys- 
temic proliferation of malignant histiocytes [ 11.  The dis- 
ease occasionally presents with isolated involvement of 
the gastrointestinal tract [2]. The distinction between MH 
and THL is at times arbitrary and the clinical syndromes 
may merge. 
The clinicopathologic studics which defined histio- 
cytic neoplasms were performed prior to the development 
of immunologic and molecular techniques now used to 
properly classify hematopoietic malignancies. We evalu- 
ated nine patients from the University of Minnesota orig- 
inally diagnosed with MH using a broad panel of antibod- 
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ies reactive with B cell, T cell, and myelomonocytic 
antigens. Only one of nine patients analyzed was reclas- 
sified as a possible histiocytic malignancy [3]. Similar 
immunophenotyping studies also have shown most cases 
previously diagnosed as MH or THL by clinical and 
morphologic criteria are in fact Ki-1 anaplastic large cell 
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TABLE I. Criteria Used for Diagnosis of True Malignant Histiocytosis 
Immunophenotyping 
Cells are negative for T and B cell-associated antigens, and express antigens associated with monocyte/macrophage origin including 
Myelomonocytic antigens: 
Monocyte-macrophage antigens: 
Antibodies associated with other lineages which may show reactivity with cells of monocytelmacrophage lineage: 
CDllb,  CDllc,  CD13, CD14, CD15, CD33, lysozyme 
CD36, CD68, MAC-387, a,-antitrypsin, a,-antichymotrypsin 
HLA-DR, CD43, CD45R0, CD45 (LCA), CD74 
Gene rearrangement studies" 
aIt is generally assumed that Ig and TcR gene rearrangements are only functional in B and T cells, respectively. We also have used this as 
criterion. Nevertheless, we are aware of the fact that such rearrangements have been described to occur occasionally in cells from other lineages 
as well, known as cross-lineage rearrangements. 
Negative B immunoglobulin and T cell antigen receptor gene rearrangement studies 
lymphoma (ALCL) or some other hematopoietic neo- 
plasm [&13]. While these results point to the rarity of 
these entities, sporadic cases exist which meet contempo- 
rary criteria for a malignant histiocytic disorder [14-18]. 
As most cases of MH and THL are now proven to be a 
heterogeneous group of other hematologic disorders, the 
clinical features traditionally associated with these syn- 
dromes should also be questioned. In this article we re- 
view the current literature on histiocytic malignancies, 
including our experience at University of Minnesota and 
other reevaluation studies, to illustrate the overall rarity 
of these neoplasms. The clinical presentation of patients 
determined to have true histiocytic malignancies by con- 
temporary criteria are evaluated and discussed. Given the 
frequent overlap of these entities, the presenting feature 
of THL and MH will be discussed together under one 
category of true histiocytic malignancies. 
MATERIALS AND METHODS 
Reevaluation of Patients From University of 
Minnesota Previously Diagnosed With 
Malignant Histiocytosis 
From 1967 to 1992 14 patients were diagnosed with 
MH at the University of Minnesota. The diagnosis was 
originally made by clinical examination, laboratory find- 
ings, radiographic studies, and morphologic interpreta- 
tion of hematoxylin and eosin-stained biopsy sections. 
In 1992 we reanalyzed the pathologic characteristics 
of these patients incorporating a large panel of immuno- 
peroxidase antibody stains reactive against B cell, T cell, 
and myelomonocytic antigens on archival paraffin- 
embedded tissue. Detailed results of this study are pub- 
lished elsewhere [3]. 
In brief, the antibodies used included CD30 (ber H2/ 
Ki-1), EMA (epithelial cells, some lymphomas), CD45 
(pan hematopietic), CD20 (B cell), CDw75 (B cell), 
CD74 (B cell), MB-2 (B cell), K, A, CD45RO (T cell), 
CD3 (T cell), MT-1 (T cell), lysozyme (myelomono- 
cytic), a,-antitrypsin and a,-antichymotrypsin (mono- 
c yte/macrophage) , CD68 (monocyte/macrophage) , 
CD36 (monocyte/macrophage), CD 15 (myelomono- 
cytic, Reed Sternberg cells), and S-100 (neural origin 
cells, Langerhans cells). Frozen material for gene rear- 
rangement studies was unavailable. 
Literature Review and Criteria for Inclusion as True 
Histiocytic Malignancy 
A medline computerized search was conducted to 
identify studies and case reports of MH or THL. Patients 
were determined to have a true histiocytic malignancy 
only when strict criteria was met as outlined by Weiss and 
others [ 19,201 (Table I). Histiocytic malignancies are 
negative for pan B and T cell markers by immunopheno- 
typing and show expression of multiple monocyte/ 
macrophage associated antigens including CD 1 1 b, 
CDllc,  CD13, CD14, CD15, CD33, CD36, CD68, and 
MAC-387. Cytoplasmic enzymes such as a,-antitrypsin, 
a,-antichymotrypsin, or lysozyme are often present but 
are not specific enough to determine histiocytic lineage 
[ 161. Isolated reactivity with antibodies associated with B 
or T lineage known to crossreact with cells of monocyte/ 
macrophage lineage is acceptable, but expression of mul- 
tiple B or T cell markers suggests lymphoid lineage. 
When air-dried material is available, the cells are positive 
for nonspecific esterase, and negative for myeloperoxi- 
dase. 
As lymphomas lacking T or B cell antigens, with or 
without expression of histiocytic markers, may show ev- 
idence of lymphoid lineage by gene rearrangement stud- 
ies [4,7,8,21], cases lacking gene rearrangement analysis 
were not included [22-271. Patients developing acute 
monocytic leukemia after an initial diagnosis of MH or 
THL were excluded as these most likely represent granu- 
locytic sarcomas [28,29]. Patients diagnosed with a ma- 
lignant histocytic disorder who had evidence of B or T 
cell lineage by immunophenotyping or gene rearrange- 
ment studies were also excluded [30]. 
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The clinical features of patients meeting all criteria for 
true histiocytic neoplasms are listed in Table 111. Most 
patients presented with one or two sites of focal involve- 
ment with a high incidence of extranodal presentation. 
Cytopenias and systemic symptoms were sporadically 
noted. Hepatosplenomegaly was absent with isolated 
splenomegaly noted in 2 patients. Only one of seven 
patients presented with a clinical syndrome resembling 
MH including splenomegaly , lymphadenopathy, pancy- 
topenia, fever, and systemic symptoms. 
Of the several published studies excluded for lack of 
gene rearrangement analysis, two studies warrant further 
discussion given the large numbers of patients in those 
series. Sonneveld et al. [ l l ]  described 12 patients who 
retained the diagnosis of MH after reevaluation by immu- 
noperoxidase studies. These patients presented with a 
clinical syndrome resembling MH , including lymphaden- 
opathy (92%), splenomegaly (loo%), hepatomegaly 
(75%), thrombocytopenia (92%), anemia (92%), leuko- 
cytopenia (67%), and fever. A similar retrospective study 
of seven patients reclassified as MH by immunopheno- 
typing reports a lower incidence of presenting features 
associated with MH [ 121. All patiens had fever and gen- 
eralized lymphadenopathy and 50% reported weight loss. 
Splenomegaly was noted in 42% and hepatospleno- 
megaly in 28%. No comment was made on hematologic 
data. While these last two studies may represent true 
histiocytic neoplasms, generalizations concerning these 
data should be guarded. Gene rearrangement studies were 
not performed and a lymphoid lineage is not entirely 
ruled out. 
Clinical Presentation of Patients With CD30 positive 
(Ki-I Associated Antigen) Lymphomas of Histiocytic 
lineage by Contemporary Diagnostic Techniques 
Patients with Ki- 1 positive anaplastic lymphoma gen- 
erally show evidence of T or B cell lineage with some 
patients demonstrating a mixed or indeterminate lineage. 
Review of the literature reveals an unusual subset of 
CD30+ lymphomas with expression of monocyte- 
macrophage-associated antigens which lack evidence of 
T or B cell lineage by immunophenotyping or gene rear- 
rangement studies [9,15,3 1,321. The clinical features of 
this group were further evaluated to determine if this 
category of neoplasms is clinically unique. 
As seen in Table IV, most patients presented with one 
or more sites of focal involvement with a high incidence 
of lymph node and extranodal involvement. Except for 
one patient, hepatosplenomegaly was not a feature of 
these patients and systemic features were sporadically 
reported. Hematologic data were not provided. One pa- 
tient presented with a clinical syndrome resembling MH 
including hepatomegaly, lymphadenopathy, systemic 
symptoms, and a disseminated neoplasm. 
RESULTS 
Reevaluation of Patients From University of 
Minnesota Previously Diagnosed With 
Malignant Histiocytosis 
Nine of 14 patients diagnosed with MH at the Univer- 
sity of Minnesota had complete clinical and pathologic 
data available for review. Eight of  the nine patients orig- 
inally diagnosed with MH were reclassified as having 
other hematologic malignancies based on the immuno- 
peroxidase antibody studies. The results of this study are 
summarized in Table I1 and discussed below along with 
other reevaluation studies. One patient had a neoplasm of 
possible histiocytic origin by immunophenotyping. How- 
ever, gene rearrangement studies were not performed and 
the true lineage is therefore uncertain. 
Summary of literature Review of the 
Reevaluation Studies 
Eleven studies, including ours, have retrospectively 
analyzed and reclassified cases previously diagnosed as 
histiocytic malignancies using immunophenotyping or 
gene rearrangement analysis. The results of these studies 
are summarized in Table 11. Approximately 164 cases of 
MH or THL have been analyzcd with the majority of 
cases being reclassified into Ki- I ALCL (1 14 cases), T or 
B cell lymphomas (24 cases), or some other category of 
hematopoietic disorder (7 cases). Nineteen cases retained 
the diagnosis of MH/THL after reevaluation. These cases 
were negative for B and T cel1 markers and expressed 
monocyte-macrophage-associated antigens by immu- 
nophenotyping . Gene rearrangement studies, however, 
were not performed and the possibility of a B or T cell 
lymphoma cannot be ruled out. Nine cases were reclassi- 
fied as Ki-1 lymphoma of possible histiocytic lineage. 
These cases were negative for B and T cell markers and 
expressed monocyte-macrophage-associated antigens in 
addition to CD30 (Ki-1 antigen). With the exception of 
one case, gene rearrangement studies were not performed 
and a lymphoid lineage for these lesions cannot be ruled 
out [9]. Tumor cells in the case with gene rearrangement 
studies expressed histiocytic antigens and lacked evi- 
dence of B or T cell lineage by immunophenotyping or 
gene rearrangement studies. This case is discussed below 
under Ki- 1 positive lymphomas of possible histiocytic 
lineage. 
Clinical Presentation of Patients With True Histiocytic 
Malignancies Determined by Contemporary 
Diagnostic Techniques 
Application of the criteria for true histiocytic tumors to 
published cases of MH or THL reveals several cases 
which appear histiocytic in origin by immunophenotyp- 
ing, but marked paucity of cases where B or T lineage has 
been excluded by gene rearrangcment studies. 
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Weiss et al., 1985 [Sib 
Isaccson et al., 1985 [6] 
Delsol et al., 1988 [7]' 
Cattoretti et al., 1990 [8] 
Van der Valk et al., 1990 [9Id 
Wilson et al., 1990 [lo] 
Sonneveld et al., 1990 [11Ie 
Hsu et al., 1991 [121' 
6 
4 
27 
10 
12 
15 
12 
13 
TABLE 11. Results of Malignant Histiocytosis Reevaluation Studies" 
Number of 
Method of reevaluation New diagnosis Reference cases 
Stein et al., 1985 (41" 4s Immunopheno typing, 35 Ki-1 lymphoma, T cell type 
7 Ki-1 lymphoma, B cell type 
3 Ki-1 lymphoma, uncertain or 
limited gene 
rearrangement studies 
mixed lineage 
Immunophenotyping, 4 T cell lymphoma 
1 B cell lymphoma 
1 unclassified (possible 1R) 
3 T cell lymphoma 
12 Ki-1 lymphoma, T cell type 
4 Ki-l lymphoma, B cell type 
11 Ki-1 lymphoma, uncertain or 
gene rearrangement studies 
Immunophenotyping 1 unclassified 
Immunophenotyping 
gene rearrangement studies 
mixed lineage 
Immunophenotyping 5 T cell lymphoma 
Immunophenotyping 2 B cell lymphomas 
gene rearrangement studies 
gene rearrangement studies 
5 Ki-1 lymphoma, uncertain lineage 
1 probable B cell lymphoma 
1 T cell lymphoma 
1 unclassified 
4 Ki-l lymphoma, T cell type 
2 Ki-1 lymphoma, probable T cell type 
1 Ki-1 lymphoma, possible 
histiocytic lineage 
3 T cell lymphoma 
2 B cell lymphoma 
6 Ki-1 lymphoma, T cell type 
2 Ki- 1 lymphoma, uncertain lineage 
1 IAHS 
1 unclassified 
12 malignant histiocytosis 
6 malignant histiocytosis 
7 Ki-1 lymphoma, histiocytic lineage 
Immunophenotyping 
Immunophenotyping 
Immunophenot yping 
limited gene 
rearrangement studies 
Immunophenotyping 
Immunophenotyping 
Nezelof et at., 1992 [13]' 
Own patients [3] 
11 
9 
1 Ki-l lymphoma, possible T cell type 
9 Ki-1 lymphoma, histiocytic lineage 
1 unclassified (questionable 
1 Ki-l lymphoma, T cell type 
2 Ki-1 lymphoma, B cell type 
2 Ki-1 lymphoma, lineage indeterminate 
2 AML (FAB M5) 
1 unclassified 
1 possible histiocytic neoplasm 
Ki-1 positivity) 
*IAHS, infectious associated hemophagocytic syndrome; IR, interdigitating reticulum cell. 
"Majority of cases originally diagnosed as MH, exact number not stated. Evaluation for immunoglobulin heavy chain rearrangement only. 
hCD30 studies were not done. 
'Only 27 of 63 cases had complete immunophenotyping data. The exact number of these cases which were previously diagnosed as MH is not stated. 
dIncludes one case of Ki-1 positive lymphoma with expression of monocyte-macrophage numbers by immunophenotyping (IP) and lack of T 
cell or B cell differentiation by IP or gene rearrangement studies. This case is included in Table IV. 
ePossibility of T or B cell lineage not ruled out by gene rearrangement studies. 
'Malignant cells lack T and B cell markers and express histiocytic antigens. Gene rearrangement studies done in only S of 13 cases; exact cases 
not specified. 
One study excluded from Table IV due to lack of gene 
rearrangement studies warrants further discussion given 
the large number of patients in this series [13]. The clini- 
cal features of 20 patients with CD30+ lymphoma of 
histiocytic lineage by immunophenotyping are described. 
Patients in this group presented with a high incidence 
of lymphadenopathy (95%) and systemic symptoms 
(75%). Splenomegaly, hepatomegaly, and pancytopenia 
were noted in 30 to 40% of patients. As stated in the pre- 
vious section, while cases from this study may represent 
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TABLE 111. Clinical Features at Presentation of Patients With Possible Histiocvtic Malignancies* 
Fever 
andlor 
systemic Pos 
Spl Lym Biop BM Rx 
S tudylcase 
number 
Ralfkiaer et al., 1990 [ 141 
Sedage S u r v i v a 1 symptoms Pan Hep 
MI73 
MI75 
MI57 
No NO - 
No NO - 
No NO - 
+I- - Sk + Chemotherapy 
- Sk, Lu - None 
- - Sk - Chemotherapy 
- 
6 months 
0.5 months 
5 months 
L 
3 
4 
Levine et al., 1991 [5] 
MI30 Yes NA - - - Med - Chemotherapy 
ABMT 
18 months L 
Kamesaki et al., 1988 [16] 
Milchgrub et al., 1992 [I71 
Franchino et al., 1988 [I81 
1 
I 
1 
F14 1 Yes Yes - + + Lym - Chemotherapy 3 months 
MI60 
MI38 
NA NA - - + I1 mass - Chemotherapy 
+ - SD1 - SDlenectomv 
DF 2 years 
No Yes - DF 13 months 
*Includes only patients with expression o f  mcinocyte-macrophage-associated antigens, lack of T or B cell antigens, and negative T and B cell 
gene rearrangement studies. Pan, pancytopenia; Hep, hepatomegaly; Spl, splenomegaly; Lym, lymphadenopathy; Pos Biop, positive biopsy; 
BM, hone marrow; Rx, treatment; Sk, skin: Lu, lungs; Med, mediastinum; 11, ileal; ABMT, autologous hone marrow transplantation; DF, disease 
free; NA, not addressed. 
TABLE IV. Clinical Features at Presentation of Patients With Possible Histiocytic Malignancies Expressing CD30 
(Ki-1LAssociated Antisen* 
Fever 
and/or 
systemic 
symptoms Pan Hep Spl Lym 
S tudylcase 
number Sexlage 
Levine et al., 1991 [IS] 
4 F142 
Pos 
Biop BM Rx Survival 
No NA - - +  G1 mass - Chemotherapy DF 4 months 
LYm 
tongue - Chemotherapy Cr, NA 
Lym 
Sk - Chemotherapy Multiple 
recurr 
8 years 
6 M16X + - No NA - 
7 FI10 - - No NA - 
Carbone et al., 1990 [31] 
Banks et al., 1990 [32] 
2 MIIX 
1 FlS2 
Yes No - - +  
Yes NA + - + 
LYm - Chemotherapy DF 23 months 
Lym, hep, - Chemotherapy Expired 
kidney, no response 
ovaries at all 
Van der Valk et al., 1990 [9] 
10 NA NA NA NA NA NA NA NA NA NA 
*Includes only cases with expression of monocyte-macrophage-associated antigens, lack of T or B cell antigens, and absence of T and B cell 
receptor and B cell immunoglobulin gene rearrangement. Pan, pancytopenia; Hep, hepatomegaly; Spl, splenomegaly; Lym, lymphadenopathy; 
Pos Biop, positive biopsy; BM, bone m;irrow; Rx, treatment; Sk, skin; GI, gluteal; ABMT, autologous bone marrow transplantation; DF, disease 
free; NA, not addressed. 
true histiocytic neoplasms, generalizations concerning 
these data should be guarded as B or T cell lineage is not 
ruled out. 
DISCUSSION 
The results of our study and multiple other studies 
analyzing archival tissue of cases previously diagnosed 
malignant histiocytosis/histiocytic lymphoma demon- 
strate the overall rarity of these entities. Prior to the 
availability of immunophenotyping and molecular tech- 
niques now used to classify hematopoietic neoplasms, 
MH was diagnosed on the basis of a syndrome of fever, 
wasting, pancytopenia, hepatosplenomegaly , lymphade- 
nopathy, and a systemic proliferation of malignant ap- 
pearing histiocytes. The majority of these cases are now 
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known to be Ki- 1 anaplastic large cell lymphoma or some 
other hematologic disorder. The clinical features tradi- 
tionally associated with histiocytic neoplasms should also 
be questioned and necessitates further evaluation. 
While these studies demonstrate the overall rarity of 
MH and THL, a small number of cases exist in the litera- 
ture which appear to be of histiocytic origin using current 
nosologic concepts of lymphoma and contemporary ana- 
lytic techniques. These cases express surface antigens 
associated with monocyte-histiocyte origin and lack evi- 
dence of T or B cell lineage by immunophenotyping or 
gene rearrangement studies. A group of related neo- 
plasms exists which appear to be of histiocytic origin but 
in addition express the Ki- 1 -associated antigen. The pre- 
senting clinical features of these two groups were further 
evaluated to determine the clinical features associated 
with true histiocytic neoplasms diagnosed by contempo- 
rary techniques. 
Although numbers are limited, the clinical presenta- 
tion of patients with histiocytic neoplasms is heteroge- 
neous and lacks a consistent clinical syndrome. These 
patients have one or more focal lesions with frequent 
extranodal proliferations. Fever, systemic symptoms, 
and cytopenias were sporadically reported. Patients with 
neoplasms of histiocytic lineage with CD30 antigen ex- 
pression are similar and presented with one or more focal 
sites of involvement with frequent nodal and extranodal 
proliferations. Systemic symptoms were noted in two 
patients. Hematologic data were not given. Only one 
patient from each group presented with clinical features 
resembling MH. 
These results must be viewed as preliminary as large 
numbers of patients with histiocytic neoplasms by immu- 
nophenotyping were excluded from evaluation due to 
lack of gene rearrangement studies. We feel this exclu- 
sion criteria is valid as studies have shown lymphomas 
indeterminate for B or T cell lineage by immunopheno- 
typing studies may have clonal T cell antigen or B cell 
immunoglobulin gene rearrangements. Some of these 
cases lacked B and T cell-associated antigens, express 
histiocytic antigens, and would have been misclassified 
as a histiocytic neoplasm in the absence of gene rear- 
rangement studies [5,8,9,21,33]. We recognize that gene 
rearrangements are not specific exclusively to lymphoid 
lineage and occasional myeloid tumors show gene rear- 
rangements. However, given the history of misdiagnosis 
of this entity, in this manuscript we recommended a diag- 
nosis of MH/THL be made only in cases where immu- 
nophenotyping results support a histiocytic lineage and 
the cells lack T cell or B cell related gene rearrangements 
It is of interest that most cases previously diagnosed as 
MH are Ki-1 positive anaplastic large cell lymphoma. 
While lymph node and/or skin involvement is the most 
common presentation of Ki-1 lymphoma, a small subset 
1191. 
of patients present with pancytopenia, hepatosplenome- 
galy, lymphadenopathy, fever, and wasting [8,13,34]. 
Some authors theorize the clinicopathologic syndrome 
previously described as MH may in fact represent a sub- 
set of Ki- 1 lymphoma, and suggests this subtype is recog- 
nizable on the basis of a 5q35 cytogenetic abnormality 
[35]. This theory is speculative and needs confirmation 
by further studies. Cases of Ki-1 lymphoma have been 
reported with the 5q35 cytogenetic abnormality which do 
not present with this syndrome [36,37]. 
The possibility that the present cases of histiocytic 
neoplasms may be related to a localized form of mono- 
cytic leukemia (AML M5b) cannot be excluded. It is 
known monocytic leukemia may present as a extramedul- 
lary mass without blood and marrow involvement 
[3840]. Results of immunophenotyping and gene rear- 
rangement studies would be similar in monocytic leuke- 
mia and histiocytic lymphomas. Morphologically AML 
M5b is composed of monoblasts, promonocytes, and 
monocytes. True histiocytic malignancies are reportedly 
composed of malignant appearing monocytes with 
greater variation in cell size and nuclear morphology 
[ 1 ,141, a distinction which may be difficult and arbitrary. 
Careful consideration must be given to this possibility 
before a histiocytic neoplasm is diagnosed. 
It is clear much work in the area of histiocytic malig- 
nancies remains to be done. A diagnosis of a true histio- 
cytic neoplasm should not be considered unless strict 
pathologic criteria are met as outlined in this paper. Only 
until appropriate pathologic techniques are used on all 
cases can progress be made in identifying these patients 
and determining the cell of origin, the clinical presenta- 
tion, appropriate treatment, and outcome. Once a unified 
approach in diagnosis is used the true nature of these 
neoplasms can be uncovered. 
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